Sanofi's Dramatic Leadership Shocker: CEO Hudson Out, Garijo Takes Helm in Strategic Overhaul

On Wednesday, Sanofi SA (NASDAQ:SNY) announced a major executive shakeup that sent shocks through the pharmaceutical industry. The Board of Directors has terminated CEO Paul Hudson's mandate after six years at the helm, with his official departure set for February 17, 2026. The move represents a dramatic reversal for Hudson, who was recruited in 2019 with an ambitious mandate to revitalize the company's struggling drug pipeline and reinvigorate investor confidence.

This shocker of a leadership change underscores mounting tensions between Sanofi's management and stakeholders over the company's strategic direction and financial performance. The decision to bring in new leadership signals the Board's assessment that a fresh approach is urgently needed to address deepening business challenges.

Belén Garijo's Appointment: From Merck Success to Sanofi Turnaround

Belén Garijo will assume the role of Chief Executive Officer effective April 29, 2026, following the Group's Annual General Meeting. She brings formidable credentials to the role, having led Merck KGaA since 2021—a historic achievement as the first woman to head a DAX40-listed company in Germany. During her tenure at Merck, Garijo established herself as a results-oriented executive capable of navigating complex pharmaceutical markets.

The Board has appointed Olivier Charmeil, Executive Vice President for General Medicines, as Interim CEO during the transition period to maintain organizational continuity. Garijo's mandate is explicit: inject renewed rigor into Sanofi's strategy execution and accelerate R&D capabilities. Her appointment signals the Board's priority to strengthen Research & Development's innovation capacity and governance frameworks—a pointed acknowledgment that Hudson-era leadership fell short of expectations.

Dupixent Dilemma: Why Revenue Concentration Triggered Leadership Crisis

The catalyst for Hudson's departure lies in Sanofi's dangerous over-reliance on a single blockbuster drug: Dupixent, the company's eczema treatment. While Dupixent delivered impressive Q4 2025 sales of €4.2 billion (up 32.2%), this concentration of revenue has become a strategic liability rather than a strength. According to François-Xavier Roger, Sanofi's Chief Financial Officer, the threat is existential. "We believe we will not be able to mitigate the impact of the loss of exclusivity of Dupixent as far as sales are concerned. It's too big to be mitigated," Roger stated to Reuters.

Investor pressure mounted as Hudson struggled to develop credible alternatives or diversify revenue streams. The company's inability to reduce this dependency became the core vulnerability that ultimately prompted the Board's intervention. Dupixent's patent cliff looms as a critical inflection point that will severely test Sanofi's financial stability if adequate counter-measures are not deployed.

Vaccine Portfolio Under Strain: Q4 Performance Signals Structural Challenges

Sanofi's vaccine division, once a growth engine, is now showing signs of structural stress. Q4 2025 vaccine sales declined 2.5% to €2 billion, reflecting softening demand across key products. The performance breakdown reveals troubling patterns:

• Beyfortus (respiratory syncytial virus vaccine) generated €686 million in Q4, representing a concerning 14.9% decline
• Influenza and COVID-19 vaccine sales rose 31.5% to €575 million, the lone bright spot in an otherwise challenging quarter
• Polio/Pertussis/Hib (PPH) vaccines fell 9.5% to €551 million, burdened by demographic headwinds including fewer infant births across multiple countries, notably China

These vaccine challenges compound the Dupixent revenue risk, creating a dual-front crisis that likely accelerated the Board's decision to replace Hudson. The vaccine portfolio weakness, combined with pipeline uncertainties, left the market questioning management's ability to navigate turbulent conditions.

Pipeline Prospects: Can Amlitelimab Become Dupixent's Successor?

Sanofi's pipeline development efforts center on amlitelimab, positioned as a potential successor to Dupixent for treating moderate-to-severe atopic dermatitis in patients 12 years and older. The company has released clinical data suggesting amlitelimab's viability, though it remains years away from potential market contribution at scale.

The critical question for Garijo's tenure is whether amlitelimab can generate sufficient revenue to offset Dupixent's anticipated decline post-exclusivity loss. If not, Sanofi faces a revenue cliff that could reshape its market valuation. This pipeline pressure adds urgency to Garijo's mandate and explains the Board's decisive action to implement leadership change before the crisis fully materializes.

Market Reaction and Investor Implications

The market's initial response was negative, reflecting investor skepticism about near-term performance. Sanofi shares declined 6.25% to $46.17 during premarket trading on Thursday following the announcement—a clear signal that markets view this leadership transition as evidence of deeper operational challenges rather than a confidence-restoring move.

Garijo's track record at Merck and her mandate to strengthen governance and innovation provide some reassurance to shareholders. However, the fundamental challenge remains: Sanofi must execute a credible transition away from Dupixent dependency while simultaneously revitalizing vaccine sales and advancing pipeline candidates. Whether this shocker of a CEO change catalyzes the strategic overhaul Sanofi desperately needs remains the critical question for investors monitoring the pharmaceutical sector.